Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

Journal: Nature Medicine

Published: 2020-10-05

DOI: 10.1038/s41591-020-1060-8

Affiliations: 18

Authors: 20

Go to article
Institutions Share
University of California, San Francisco (UCSF), United States of America (USA) 0.10
Fred Hutchinson Cancer Research Center (FHCRC), United States of America (USA) 0.10
University of California, Los Angeles (UCLA), United States of America (USA) 0.10
Dwight D. Eisenhower Army Medical Center, United States of America (USA) 0.05
Medical College of Wisconsin (MCW), United States of America (USA) 0.05
University of Arkansas at Little Rock (UALR), United States of America (USA) 0.05
University of Michigan (U-M), United States of America (USA) 0.05
Cancer Center of Kansas, United States of America (USA) 0.05
Messino Cancer Centers, United States of America (USA) 0.05
Loyola University Chicago (LUC), United States of America (USA) 0.05
KU Cancer Center, United States of America (USA) 0.05
The Ohio State University (OSU), United States of America (USA) 0.05
The University of Alabama at Birmingham (UAB), United States of America (USA) 0.05
Kaiser Permanente, United States of America (USA) 0.05
Rutgers Biomedical and Health Sciences (RBHS), RU, United States of America (USA) 0.05
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA) 0.05
Missouri Baptist Medical Center, United States of America (USA) 0.03
Heartland Cancer Research NCORP, United States of America (USA) 0.03

Return